ArticleAnnals of hematology2025
Establishing prognostic markers associated with neutrophil extracellular traps and the activated contact system in thrombotic microangiopathy.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between neutrophil extracellular traps, the Von Willebrand factor axis, and clinical outcome in stable coronary artery disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic microangiopathy (TMA) is a life-threatening thrombotic disorder. Neutrophil extracellular traps (NETs) and activation of the contact system are known to promote and propagate the formation of thrombus. Our study assessed the prognostic values of multiple NET markers and a contact system activation marker in patients with clinically suspected TMA. Patients (n = 138) with clinically suspected TMA were analyzed for the circulating levels of NET markers (neutrophil elastase, histone-DNA complexes, citrullinated histone H3 [Cit H3], and cell-free double-stranded DNA [dsDNA]); the contact system activation marker (activated factor XII [factor XIIa]); and other TMA-associated markers (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 [ADAMTS13] activity, von Willebrand factor antigen [vWF:Ag], von Willebrand factor ristocetin cofactor activity [vWF:Rco], and platelet counts). Low ADAMTS13 activity (hazard ratio [HR]: 4.85, P = 0.033), high vWF:Rco (HR: 9.46, P = 0.037), low platelet counts (HR: 7.45, P = 0.017), and high histone-DNA complexes (HR: 8.43, P = 0.015) were identified as independent markers of high mortality in multivariable Cox proportional hazards regression analysis. ADAMTS13, vWF:Rco, platelet counts, and histone-DNA complexes can be useful markers for identifying TMA patients at high risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.